Aqualung Publications

Insight. Impact. Innovation.
View relevant publications demonstrating the efficacy of  ALT-100 mAb in preclinical models

ALT-100 mAb

Phase 1A Trial, ALT-100 mAb


PUERTA ARDS Phase 2 Trial, ALT-100 mAb


ARDS/Sepsis, ALT-100 mAb


Pulmonary Fibrosis, ALT-100 mAb

Hepatic Fibrosis, ALT-100 mAb

Cancer, ALT-100 mAb


Preterm Births/Chorio, ALT-100 mAb


Lupus Vasculitis, ALT-100 mAb


Pulmonary Hypertension- ALT-100 mAb

Cardiac Fibrosis / Vascular Disease, ALT-100 mAb




Trauma Induced Lung Injury, ALT-100 mAb


Radiation Induced Lung Injury, ALT-100 mAb


NTyP-100 Nanocarrier


ARDS/Sepsis, NTyP-100 Nanocarrier

SELP-100 mAb

SELP-100 mAb